SCHEMBL24019691

SCHEMBL24019691

COc1cc(Cl)c2[nH]c(C(=O)NC(C)C)cc2c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.51
KDM4E B2RXH2 4/20 0.47
ALDH1A1 P00352 3/20 0.47
MAPT P10636 3/20 0.47
CTNNB1 P35222 1/20 0.40
ALPL P05186 2/20 0.39
FLT3 P36888 2/20 0.39
LGALS8 O00214 1/20 0.39
LGALS3 P17931 1/20 0.39
PYGL P06737 1/20 0.38
PDGFRB P09619 1/20 0.38
PDGFRA P16234 1/20 0.38
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
JAK3 P52333 1/20 0.37
HPGDS O60760 1/20 0.37
HRH4 Q9H3N8 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24019966 0.85 ALOX15 (0.58) ALOX15ALDH1A1CTNNB1ALPLPYGL
SCHEMBL24019772 0.83 ALOX15 (0.53) ALOX15MAPTCTNNB1ALPLPYGL
SCHEMBL24740405 0.83 ALOX15 (0.50) ALOX15KDM4EALDH1A1MAPTHPGDS
SCHEMBL30310393 0.81 KDM4E (0.54) KDM4EALDH1A1MAPTFLT3PDGFRB
SCHEMBL24020626 0.81 KDM4E (0.54) KDM4EALDH1A1MAPTFLT3PDGFRB
SCHEMBL29062726 0.80 FLT3 (0.42) KDM4EALDH1A1MAPTFLT3PDGFRB
SCHEMBL30008705 0.80 FLT3 (0.42) KDM4EALDH1A1MAPTFLT3PDGFRB
SCHEMBL24019959 0.78 ALOX15 (0.57) ALOX15ALPLPYGLHRH4
SCHEMBL25758899 0.76 HPGDS (0.43) ALOX15KDM4EALDH1A1MAPTALPL
SCHEMBL4386339 0.76 HPGD (0.60) ALOX15KDM4EALDH1A1MAPTALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
US-11524940-B1 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2022-12-13 US disclosed
US-11174231-B1 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2021-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11174231-B1 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL ALOX15 1749/4885KDM4E 2930/4885ALDH1A1 2252/4885
US-11524940-B1 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL ALOX15 1749/4885KDM4E 2930/4885ALDH1A1 2252/4885
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSL, CTSV ALOX15 1455/4885KDM4E 3122/4885ALDH1A1 1863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.